Please ensure Javascript is enabled for purposes of website accessibility

CDC Head: Years of Underfunding Are Impeding U.S. Government's Coronavirus Response

By David Jagielski - Mar 11, 2020 at 2:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Many people have criticized the the Centers for Disease Control for its inadequate response to the fast-spreading virus.

The Centers for Disease Control and Prevention told Congress this week that insufficient federal investment in public health has impaired its ability to respond to the coronavirus pandemic. An issue with faulty test kits further reduced the availability of health care works to test those showing symptoms, and made it harder to gauge the scale of the U.S. outbreak. Further, backlogs have meant that many of those people who were tested are enduring long waits to get their results back. 

"There's not enough equipment, there's not enough people, there's not enough internal capacity, there's no search capacity," said CDC Director Robert Redfield. However, federal, state, and local government agencies have been making efforts to increase the availability of tests.

The coronavirus is becoming a more serious threat by the day. The World Health Organization officially classified it as a pandemic on Wednesday. As of 4 p.m. Tuesday, the CDC said there were 938 people in the U.S. with COVID-19, and 29 who have died from it. The Johns Hopkins University dashboard that tracks data about the disease in real time reported 1,050 U.S. cases as of mid-afternoon Wednesday.

Doctor reviewing test results with patient.

Image source: Getty Images.

Companies are providing people with more testing options

Quest Diagnostics (DGX -3.36%) is a leading medical testing company, and it announced last week that it will start offering testing for COVID-19 as early as this week. The company believes it's in a good position to help the country get a handle on the outbreak. 

"Quest's national scale, diagnostic expertise and innovation, and relationships with half the country's physicians and health systems is a vital complement to the efforts of the CDC and other public health labs to contend with a growing number of suspected COVID-19 cases in the United States," said CEO and President Steve Rusckowski 

The healthcare company has generated more than $7 billion in sales in each of the past 10 years. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
DGX
$132.98 (-3.36%) $-4.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.